ClinicalTrials.gg

Program

mibavademab

Also written as “Mibavademab”, “REGN4461” and “Low-Dose REGN4461”.

Its studies are mostly in Obesity, Morbid · Lipodystrophy, Familial Partial · Amenorrhea · Obesity, led by 2 companies.

Furthest: phase 3, since Aug 7, 20248 company-led studies, 3 open or runningNext primary completion: Jun 18, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Regeneron Pharmaceuticals73 open or runningphase 3since Aug 7, 2024May 7, 2018Jun 18, 2027phase 3 · NCT07220772
Eli Lilly10 open or runningphase 2since Apr 16, 2024Apr 16, 2024none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 7, 2018First study: phase 1 study in Healthy VolunteersNew to Regeneron PharmaceuticalsRegeneron Pharmaceuticals · NCT03530514 · 113 enrolled · Belgium
  2. Nov 7, 2019Phase 2 study in Lipodystrophy, Congenital GeneralizedRegeneron Pharmaceuticals · NCT04159415 · 16 enrolled · United States, Peru, Russia and more
  3. Oct 12, 2021Phase 2 study in Lipodystrophy, Familial PartialRegeneron Pharmaceuticals · NCT05088460 · 20 enrolled · United States, France, Spain and more
  4. Apr 16, 2024Eli Lilly's first study: phase 2 study in ObesityNew to Eli LillyEli Lilly · NCT06373146 · 392 enrolled · United States
  5. Aug 7, 2024Phase 3 study in Lipodystrophy, Congenital GeneralizedRegeneron Pharmaceuticals · NCT06548100 · 9 enrolled · United States
  6. Oct 22, 20252 phase 3 studiesRegeneron Pharmaceuticals · NCT07220785, NCT07220772
  7. Nov 14, 2025Phase 2 study in AmenorrheaRegeneron Pharmaceuticals · NCT07235917 · 34 planned · United States
  8. Oct 1, 2026Primary completion moved from 2027-08-20 to 2028-01-28Date moved laterphase 2 · +5 months · NCT07235917

Ahead

  1. Jun 18, 2027Primary completion: phase 3 study in Obesity, MorbidRegeneron Pharmaceuticals · NCT07220772
  2. Jan 28, 2028Primary completion: phase 2 study in AmenorrheaRegeneron Pharmaceuticals · NCT07235917
  3. May 19, 2028Primary completion: phase 3 study in Lipodystrophy, Congenital GeneralizedRegeneron Pharmaceuticals · NCT07220785

TargetBeta

LEPR →read by rule
“Leptin receptor agonist”ChEMBL 37, by rule

Studies

All 8 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07235917Amenorrhea · United States2RecruitingRegeneron PharmaceuticalsJan 28, 202834
NCT07220785Lipodystrophy, Congenital Generalized · United States, Brazil, France3RecruitingRegeneron PharmaceuticalsMay 19, 202828
NCT07220772Obesity, Morbid · Germany, Spain, Turkey (Türkiye)3RecruitingRegeneron PharmaceuticalsJun 18, 20274
NCT06548100Lipodystrophy, Congenital Generalized · United States3CompletedRegeneron PharmaceuticalsJul 9, 20269
NCT06373146Obesity · United States2CompletedEli LillyDec 15, 2025392
NCT05088460Lipodystrophy, Familial Partial · United States, France, Spain and more2TerminatedRegeneron PharmaceuticalsDec 13, 202320
NCT04159415Lipodystrophy, Congenital Generalized · United States, Peru, Russia and more2CompletedRegeneron PharmaceuticalsJan 5, 202216
NCT03530514Healthy Volunteers · Belgium1CompletedRegeneron PharmaceuticalsJan 27, 2020113

How it is read

Names in the registry

  • “Mibavademab”, 4 entries
  • “REGN4461”, 2 entries
  • “mibavademab”, 1 entry
  • “Low-Dose REGN4461”, 1 entry
  • “High-dose REGN4461”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.